Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.450.1%
QQQ
717.500.2%
BTC/USD
78741.200.4414%
DIA
532.880.22%
GLD
406.530.06%
TLT
82.240.04%

AbCellera Biologics Inc

ABCLNASDAQ
Trade with Public
Trade with Public
$11.43
-0.14-1.21%
At close: Sep 4, 5:00 PM EST
$11.50
0.06650.58%
After Hours: Sep 4, 7:42 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

AbCellera Biologics Analyst Price Targets

Wall Street analyst price targets and consensus rating for AbCellera Biologics (ABCL).

Price Target Range — 11 Quarters

Analyst Consensus — 8 Analysts

7Buy
1Hold
Consensus RatingBuy# Analysts8Avg. Consensus PT$13Upside to Avg. PT+13.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 11, 2026Truist SecuritiesRobyn KamausPT RaiseBuy$12→$30
Aug 6, 2026StifelStephen WilleyPT RaiseBuy$8→$9
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Truist Securities Maintains Buy on AbCellera Biologics, Raises Price Target to $30

Truist Securities analyst Robyn Kamaus maintains AbCellera Biologics (NASDAQ:ABCL) with a Buy and raises the price target from $12 to $30.
Benzinga Newsdesk

PRO
Stifel Maintains Buy on AbCellera Biologics, Raises Price Target to $9

Stifel analyst Stephen Willey maintains AbCellera Biologics (NASDAQ:ABCL) with a Buy and raises the price target from $8 to $9.
Benzinga Newsdesk

PRO
Cantor Fitzgerald Maintains Overweight on AbCellera Biologics, Raises Price Target to $12

Cantor Fitzgerald analyst Steve Seedhouse maintains AbCellera Biologics (NASDAQ:ABCL) with a Overweight and raises the price target from $11 to $12.
Benzinga Newsdesk

PRO
Benchmark Upgrades AbCellera Biologics to Buy, Announces $11 Price Target

Benchmark analyst Robert Wasserman upgrades AbCellera Biologics (NASDAQ:ABCL) from Hold to Buy and announces $11 price target.
Benzinga Newsdesk

PRO
Cantor Fitzgerald Initiates Coverage On AbCellera Biologics with Overweight Rating, Announces Price Target of $7

Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on AbCellera Biologics (NASDAQ:ABCL) with a Overweight rating and announces Price Target of $7.
Benzinga Newsdesk

PRO
Jones Trading Initiates Coverage On AbCellera Biologics with Buy Rating, Announces Price Target of $11

Jones Trading analyst Debanjana Chatterjee initiates coverage on AbCellera Biologics (NASDAQ:ABCL) with a Buy rating and announces Price Target of $11.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved